CO2021015698A2 - Moduladores de thr-β y métodos de uso de estos - Google Patents

Moduladores de thr-β y métodos de uso de estos

Info

Publication number
CO2021015698A2
CO2021015698A2 CONC2021/0015698A CO2021015698A CO2021015698A2 CO 2021015698 A2 CO2021015698 A2 CO 2021015698A2 CO 2021015698 A CO2021015698 A CO 2021015698A CO 2021015698 A2 CO2021015698 A2 CO 2021015698A2
Authority
CO
Colombia
Prior art keywords
formula
methods
thr
modulators
iiid
Prior art date
Application number
CONC2021/0015698A
Other languages
English (en)
Inventor
Koen Vandyck
Pierre Jean-Marie Bernard Raboisson
David Mcgowan
Jerome Deval
Original Assignee
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics Inc filed Critical Aligos Therapeutics Inc
Publication of CO2021015698A2 publication Critical patent/CO2021015698A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se divulgan compuestos de la Fórmula I: (I) TL-La-CE-HD o una sal, profármaco, amida o éster aceptable desde el punto de vista farmacéutico de estos, donde i) TL es una porción de la Fórmula IIa, IIb, IIIa, IIIb, IIIc o IIId; ii) CE es una porción de la Fórmula IV; iii) HD es una porción de la Fórmula V o VI; donde los sustituyentes son como se definen en la presente. También se divulgan composiciones farmacéuticas que comprenden los compuestos anteriores y métodos para tratar enfermedades mediante la administración o el contacto de un paciente con uno o más de los compuestos anteriores. (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId)
CONC2021/0015698A 2019-05-08 2021-11-23 Moduladores de thr-β y métodos de uso de estos CO2021015698A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962845252P 2019-05-08 2019-05-08
US201962944052P 2019-12-05 2019-12-05
US202063005661P 2020-04-06 2020-04-06
PCT/US2020/031904 WO2020227549A1 (en) 2019-05-08 2020-05-07 MODULATORS OF THR-β AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
CO2021015698A2 true CO2021015698A2 (es) 2022-01-17

Family

ID=70919081

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0015698A CO2021015698A2 (es) 2019-05-08 2021-11-23 Moduladores de thr-β y métodos de uso de estos

Country Status (17)

Country Link
US (2) US11091467B2 (es)
EP (1) EP3965884A1 (es)
JP (1) JP2022532706A (es)
KR (1) KR20220017917A (es)
CN (1) CN114096531A (es)
AU (1) AU2020267576A1 (es)
BR (1) BR112021021718A2 (es)
CA (1) CA3139101A1 (es)
CL (1) CL2021002883A1 (es)
CO (1) CO2021015698A2 (es)
IL (1) IL287720A (es)
MA (1) MA55890A (es)
MX (1) MX2021013472A (es)
PE (1) PE20220255A1 (es)
SG (1) SG11202111552YA (es)
TW (1) TW202108569A (es)
WO (1) WO2020227549A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021021718A2 (pt) * 2019-05-08 2022-01-18 Aligos Therapeutics Inc Moduladores de thr-ss e métodos de uso dos mesmos
JP2023503154A (ja) * 2019-11-26 2023-01-26 昆薬集団股▲フン▼有限公司 １，２，４－トリアジン－３，５－ジオン系化合物およびその製造方法と応用
CN114787153A (zh) * 2019-12-26 2022-07-22 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
AU2021341182A1 (en) * 2020-09-10 2023-04-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of resmetirom, preparation method therefor, and use thereof
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
KR20230124556A (ko) 2020-11-06 2023-08-25 알리고스 테라퓨틱스 인코포레이티드 옥신돌 및 이의 사용 방법
CA3197234A1 (en) * 2020-11-06 2022-05-12 David Craig Mcgowan Pyridazinone derivatives as thyroid receptor agonists and uses thereof
CN112645936B (zh) 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
PE20240097A1 (es) * 2021-03-03 2024-01-18 Terns Pharmaceuticals Inc Compuestos agonistas beta del receptor de la hormona tiroidea
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
WO2022242743A1 (zh) * 2021-05-21 2022-11-24 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
WO2023023474A1 (en) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
CA3230222A1 (en) 2021-09-01 2023-03-09 Leonid Beigelman Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
WO2023039076A1 (en) 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
CN116354934A (zh) * 2021-12-28 2023-06-30 中国科学院上海药物研究所 一类喹啉类化合物及其制备方法、药物组合物和用途
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
PT1088819E (pt) * 1999-09-30 2005-09-30 Pfizer Prod Inc Derivados de 6-azauracilo como lignados de receptores da tiroide
ES2267945T3 (es) 2001-05-31 2007-03-16 Pfizer Products Inc. Uso medico de compuestos tiromimeticos para tratar la perdida del cabello y composiciones.
EP1471049A4 (en) 2002-01-30 2006-08-16 Kissei Pharmaceutical NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
AU2003278544A1 (en) 2002-11-25 2004-06-18 Pfizer Products Inc. Method for promoting nail growth using thyromimetic compounds
DK1919878T3 (da) * 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
US7638531B2 (en) * 2005-12-21 2009-12-29 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
JPWO2008001959A1 (ja) * 2006-06-28 2009-12-03 株式会社三和化学研究所 新規６−５系二環式複素環誘導体及びその医薬用途
WO2008104752A1 (en) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
MX2011011028A (es) 2009-04-20 2011-11-02 Mitsubishi Tanabe Pharma Corp Agonista del receptor beta de hormona tiroidea novedoso.
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
ES2528392T3 (es) 2012-08-06 2015-02-09 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Eprotiroma para su uso en la prevención y/o tratamiento de trastornos capilares y composiciones de la misma
MX364661B (es) 2012-09-17 2019-05-03 Madrigal Pharmaceuticals Inc Metodo para sintetizar los analogos de hormona tiroidea y leucocitos polimorfonucleares de los mismos.
JP6333372B2 (ja) 2013-07-09 2018-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤の組み合わせ
US10303567B2 (en) 2013-08-15 2019-05-28 Entit Software Llc Managing database nodes
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
JP2018501276A (ja) 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
MX2018014743A (es) 2016-06-03 2019-04-11 Chemocentryx Inc Metodo para tratar fibrosis hepatica.
ES2924257T3 (es) 2016-10-18 2022-10-05 Madrigal Pharmaceuticals Inc Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta
MX2019010322A (es) 2017-03-13 2019-10-21 Genfit Composiciones farmaceuticas para el tratamiento combinado.
WO2018193007A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
JP7273022B2 (ja) 2017-07-19 2023-05-12 バイオ―ラッド ヨーロッパ ゲーエムベーハー 非アルコール性脂肪性肝炎及び肝線維症ステータスを同時に評価するバイオマーカの組み合わせ
WO2019099457A1 (en) 2017-11-14 2019-05-23 Quixgen, Inc. Benzodioxinone compounds
BR112020011431A2 (pt) 2017-12-06 2020-11-24 Basf As derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica
US11485729B2 (en) 2018-01-23 2022-11-01 Shenzhen Targetrx, Inc. Substituted pyridazinone compound
EP3765059A4 (en) 2018-03-12 2022-01-12 Yale University METHODS OF TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME
WO2019213611A1 (en) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
CN108727344A (zh) 2018-05-14 2018-11-02 嘉兴特科罗生物科技有限公司 一种化合物及其合成方法和应用
AU2019287679B2 (en) 2018-06-12 2022-04-21 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
EP3806832A1 (en) 2018-06-14 2021-04-21 Alma Mater Studiorum - Università di Bologna Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug
CN110627773B (zh) 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
TW202019914A (zh) 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
WO2020041741A1 (en) 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN112739692A (zh) * 2018-10-12 2021-04-30 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CA3114015A1 (en) 2018-10-12 2020-04-16 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
US20220162161A1 (en) * 2019-02-21 2022-05-26 Nanjing Ruijie Pharma Co., Ltd. Novel compounds and their uses as thyroid hormone receptor agonists
BR112021021718A2 (pt) * 2019-05-08 2022-01-18 Aligos Therapeutics Inc Moduladores de thr-ss e métodos de uso dos mesmos
WO2020228577A1 (zh) 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
IT201900006923A1 (it) 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
TW202115029A (zh) 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途
WO2021032218A1 (zh) 2019-08-19 2021-02-25 苏州闻天医药科技有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN112442013B (zh) 2019-09-04 2022-07-26 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
EP4036090A4 (en) 2019-09-24 2023-11-15 Sunshine Lake Pharma Co., Ltd. CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF

Also Published As

Publication number Publication date
SG11202111552YA (en) 2021-11-29
IL287720A (en) 2021-12-01
WO2020227549A8 (en) 2021-05-27
CL2021002883A1 (es) 2022-10-28
US11091467B2 (en) 2021-08-17
CA3139101A1 (en) 2020-11-12
BR112021021718A2 (pt) 2022-01-18
US20210355112A1 (en) 2021-11-18
US20200354345A1 (en) 2020-11-12
KR20220017917A (ko) 2022-02-14
WO2020227549A1 (en) 2020-11-12
CN114096531A (zh) 2022-02-25
MX2021013472A (es) 2022-01-06
AU2020267576A1 (en) 2021-12-09
TW202108569A (zh) 2021-03-01
JP2022532706A (ja) 2022-07-19
EP3965884A1 (en) 2022-03-16
PE20220255A1 (es) 2022-02-16
MA55890A (fr) 2022-03-16

Similar Documents

Publication Publication Date Title
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
PE20221910A1 (es) Derivados de pirazolilo utiles como agentes anticancerigenos
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
AR116604A1 (es) Inhibidores de kras g12c
DOP2022000117A (es) Inhibidores de kras g12c
PE20210176A1 (es) Inhibidores de arginasa y sus metodos de uso
UY39261A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
CO2021014210A2 (es) Compuestos de pirrol
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR119857A1 (es) Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak
CO2022004391A2 (es) Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4
ECSP23089582A (es) Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio
CO2021017202A2 (es) Compuestos tricíclicos
CO2021011039A2 (es) Inhibidores de arginasa y métodos de uso de estos
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
DOP2023000209A (es) Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3